Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-11-05
Ethical passes the values gate
Price108.34 USD
Fair value122.00Our model only; only one analyst covers it, too few to cross-check it.
Ethical score90.3/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation99.12+9.3% to today ✓Markdown gives way to Accumulation after a 7% slide in 5 weeks
2026-09-04Read Markdown106.13+2.1% to today Markup gives way to Markdown with volume flow in agreement
2026-08-04Read Markup105.65+2.5% to today ✓Accumulation gives way to Markup after a 13% rise in 5 weeks
2026-07-02Read Accumulation93.35+16.1% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Liberty Live Holdings, Inc. holds its Accumulation at $108.34. Consolidating, no directional conviction, held for 247 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 247 days
Price at the screen
$108.34
Valuation
N/A trailing · -31.32 forward price to earnings
Values screen
PASS· score 90.3
Beta
0.97
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
19.93%
Below 33%
Interest-bearing debt is just 19.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.75%
Below 33%
Cash held in interest-bearing accounts and securities is 5.7% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
4.11%
Below 5%
Only 4.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Liberty Live Holdings, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and interest is about 4% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LLYVK's ethical verdict changes
Today LLYVK passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly an 11% discount to our $122.00 fair value, 6.10% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 11.2% discount to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Where our models see it going: fair-value estimate $122.00, range not available, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Live events group still deep in losses
Picture a packed arena where the ticket, the beer and the merch all flow through one set of hands. Liberty Live sits in that chain, running venues, managing talent and selling seats across the US live-music circuit.
Revenue is climbing 35 percent, which stands out in a patchy recovery for live entertainment. The shares sit 12 percent below our fair-value mark, yet the business is still posting an 88 percent negative profit margin and a deeply negative forward multiple, so the market is giving it little credit for the growth.
The real risk is the cash burn and the thin analyst coverage. One voice sets the $115 target, and any slowdown in concert spending would hit margins hard before growth can turn into profit. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LLYVK trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$110.35+4.2%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Accumulation$105.87+1.1%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$104.73+0.3%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$104.37+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$104.37+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$104.37+0.9%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$103.40+2.3%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$101.07+3.1%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$98.05-1.6%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115.
2026-10-18Accumulation$99.66+0.5%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (1 analysts) rates it strong buy, with a mean price target of $115.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
